SCHEMBL8737302

SCHEMBL8737302

Cc1ccc(Oc2ccc3c(c2)C(=O)N(C)C3=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 1/20 0.61
LPAR3 Q9UBY5 1/20 0.61
APP P05067 2/20 0.56
ALDH1A1 P00352 6/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
KDM4E B2RXH2 2/20 0.51
POLB P06746 2/20 0.51
HTT P42858 1/20 0.51
GAA P10253 1/20 0.51
HSD17B10 Q99714 2/20 0.50
MAPK1 P28482 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
GRIA2 P42262 1/20 0.48
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
MAPT P10636 1/20 0.45
ALOX15 P16050 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
APAF1 O14727 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12799185 0.97 LPAR1 (0.58) LPAR1LPAR3APPALDH1A1MEN1
SCHEMBL14106913 0.94 ALDH1A1 (0.56) LPAR1LPAR3APPALDH1A1MEN1
SCHEMBL262253 0.93 ALDH1A1 (0.57) LPAR1LPAR3APPALDH1A1MEN1
SCHEMBL760105 0.91 MEN1 (0.64) LPAR1LPAR3APPALDH1A1MEN1
SCHEMBL13899502 0.89 LPAR1 (0.52) LPAR1LPAR3APPALDH1A1MEN1
SCHEMBL18117700 0.89 ALDH1A1 (0.51) LPAR1LPAR3APPALDH1A1MEN1
SCHEMBL5020550 0.89 MEN1 (0.65) LPAR1LPAR3APPALDH1A1MEN1
SCHEMBL13023418 0.88 MEN1 (0.61) LPAR1LPAR3APPALDH1A1MEN1
SCHEMBL11095064 0.88 MAOA (0.60) LPAR1LPAR3APPALDH1A1MEN1
SCHEMBL14010053 0.87 BRD4 (0.58) LPAR1LPAR3APPALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016173902-A1 POLYMER COMPOSITIONS BASED ON A BIO-SOURCED POLYARYLENE ETHER KETONE SOLVAY SPECIALTY POLYMERS USA, LLC (US) 2016-11-03 WO disclosed
US-9381177-B2 Substituted N-(2-arylamino)aryl sulfonamide-containing combinations BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-07-05 US disclosed
US-20140329866-A1 OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHCARE LLC (US) 2014-11-06 US disclosed
US-8841330-B2 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER HEALTHCARE LLC (US) 2014-09-23 US disclosed
US-8623513-B2 Hydrophobic polyetherimide/polysiloxane copolymer intermediate transfer components XEROX CORPORATION (US) 2014-01-07 US disclosed
US-8623513-B2 Hydrophobic polyetherimide/polysiloxane copolymer intermediate transfer components XEROX CORPORATION (US) 2014-01-07 US disclosed
US-20130261120-A1 SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-10-03 US disclosed
US-20120142742-A1 OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHERCARE LLC (US) 2012-06-07 US disclosed
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20080032979-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors BAYER HEALTHCARE LLC 2008-02-07 US disclosed
US-20080027061-A1 omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors BAYER HEALTHCARE LLC 2008-01-31 US disclosed
EP-1636585-B1 DIARYL UREAS WITH KINASE INHIBITING ACTIVITY BAYER PHARMACEUTICALS CORP (US) 2008-01-16 EP disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-7235576-B1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2007-06-26 US disclosed
WO-2007053574-A2 COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER BAYER PHARMACEUTICALS CORPORATION (US) 2007-05-10 WO disclosed
US-20070020704-A1 Diaryl ureas with kinase inhibiting activity BAYER HEALTHCARE LLC 2007-01-25 US disclosed
US-4217281-A Imide carbonyl compounds and method for making GENERAL ELECTRIC COMPANY (US) 1980-08-12 US disclosed
US-4128574-A FROM AN IMIDE GENERAL ELECTRIC COMPANY (US) 1978-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032979-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors BRAF, NRAS, RAF1 LPAR1 1074/4885LPAR3 742/4885APP 3676/4885
US-20070020704-A1 Diaryl ureas with kinase inhibiting activity FLT4, FLT1, FLT3 LPAR1 3047/4885LPAR3 1544/4885APP 3690/4885
US-20080027061-A1 omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors MAPK1, MAPK8, MAPK3 LPAR1 691/4885LPAR3 782/4885APP 2990/4885
US-20130261120-A1 SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS KIT, CHUK, IKBKB LPAR1 1942/4885LPAR3 1429/4885APP 4257/4885
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BRAF, RAF1, ARAF LPAR1 3481/4885LPAR3 3550/4885APP 4789/4885
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas BRAF, RAF1, ARAF LPAR1 3481/4885LPAR3 3550/4885APP 4789/4885
US-20140329866-A1 OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF LPAR1 579/4885LPAR3 807/4885APP 3625/4885
US-20120142742-A1 OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF LPAR1 1167/4885LPAR3 907/4885APP 3545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.